Efficacy and safety of VEGFR inhibitors for recurrent ovarian cancer: a systematic review-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Efficacy and safety of VEGFR inhibitors for recurrent ovarian cancer: a systematic review

Published:2024-08-12 Issue: Volume: Page:1-19
ISSN:1479-6694
Container-title:Future Oncology
language:en
Short-container-title:Future Oncology

Author:

Tan Linlin¹²^ORCID,Ni Yuchun¹,Huang Zhaowei³,Yan Jiaqi¹,Wu Mei⁴,Zhang Zhipeng³,Zhang Fupeng¹³,Wang Zhijie¹^ORCID

Affiliation:

1. Shanxi Hospital of Traditional Chinese Medicine,Taiyuan,Shanxi Province,030000,China

2. Jinshazhou Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong Province, 510000, China

3. Shanghai University of Traditional Chinese Medicine, Shanghai, 200120, China

4. Shanxi University of Chinese Medicine, Taiyuan, Shanxi Province, 030000, China

Funder

Scientific Research Project of Shanxi Provincial Health Commission

Administration of Traditional Chinese Medicine of Shanxi Province

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/14796694.2024.2373680

Reference77 articles.

1. Treatment of epithelial ovarian cancer

2. Incidence and mortality of ovarian cancer at the global, regional, and national levels, 1990–2017

3. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

4. Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer

5. Tumor–Host Cell Interactions in Ovarian Cancer: Pathways to Therapy Failure

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP